In patients with severe hepatic impairment (Child-Pugh1 score of 10 or greater), clearance is reduced twofold to
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment
Ondansetron comes in three forms that
3 ZOFRAN ® 4 (ondansetron hydrochloride) 112 half-life is increased to 11
The calculated elimination half-life of subcutaneous ondansetron was significantly longer ( P < 0
Here are the formula's different components: N (t) represents the remaining quantity of
S
6 to 15
Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3
381 61-74 12 106 4
In clinical trials with cancer patients, safety and efficacy were similar in patients Zofran; Zofran ODT; Zuplenz; Descriptions
Strikingly, there is no correlation between plasma concentrations of ondansetron and the level of efficacy
A reduction in clearance and increase in elimination half-life are seen in patients over 75
5 half-lives for a drug to be completely eliminated from your system
In The half-life of aprepitant is approximately 25% lower in females as compared with males and T max occurs at approximately the same time
The lack of effect on PONV in our study setting might also have been related to the short half-life of ondansetron (4–6 hours) and to the fact that IT morphine-induced PONV can last for a much longer period (up to 24 hours)
A headache, hypoxia, and fever are some of the more commonly reported side effects
8 hours
15 years); 3-7 hr (adults); patients with mild to moderate hepatic impairment, 12 hr; patients with severe hepatic impairment (Child
SIN Page 4 of 15 The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine
The onset of action following a single intravenous dose Half life 4-9 hours; Extensive hepatic metabolism; Renal and hepatic excretion (dose reduction is required for hepatic insufficiency) Clinical uses
15 mg/kg of ondansetron at 4-hour intervals, patients older than 15 years exhibited ondansetron Lorazepam is FDA-approved for short-term (4 months) relief of anxiety symptoms related to anxiety disorders, anxiety-associated insomnia, anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia, and treatment of status epilepticus
6 hours compared to 5
1 to 11
Extent of absorption following intramuscular injection into a lateral compartment of the thigh is identical to intravenous injection and absorption is rapid with T What is the half life of Zofran? Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3
tired feeling